Half-dose photodynamic therapy for the treatment of chronic central serous chorioretinopathy had superior results when compared with high-density subthreshold micropulse laser treatments.
The PLACE trial, an open-label, multicenter, randomized controlled clinical trial, included 179 patients with chronic central serous chorioretinopathy who were randomly assigned 1:1 to half-dose PDT or high-density subthreshold micropulse laser (HSML) treatment.
At the first evaluation, a significantly higher percentage of PDT patients experienced complete resolution of subretinal fluid, the primary endpoint
Uncategorized